Ark Therapeutics Group PLC
Description Ark Therapeutics Group plc, a gene-based medicine company, engages in the discovery, development, and commercialization of products in the areas of specialist medicine, primarily focusing on vascular disease and cancer in Europe. The company offers product development and good manufacturing practice manufacturing contract services for viral products, including the areas of viral mediated gene therapy, oncolytic viral vaccines, live and attenuated viral vaccines, viral vectored vaccines, and virus like particles. Its gene therapy products include Cerepro, a novel gene-based product for the treatment of patients with operable high grade glioma, a type of malignant brain tumour; and Trinam, a novel product, which consists of a delivery device and a gene-based medicine to prevent the blocking of blood vessels that occurs after vascular surgery. The gene therapy products also comprise EG013 for fetal growth restriction, EG011 for refractory angina, and EG016 for peripheral vascular disease, which are under various clinical trials. In addition, the company develops small molecules in vascular biology, including Neuropilin-1 antagonist for cancer therapy and other small molecule therapeutics in vascular biology. Ark Therapeutics Group plc was founded in 1997 and is based in London, the United Kingdom. To view the detailed information, you need to SUBSCRIBE with us. |
 |